Skip to content
Gold Mining News – Lifestyle
Home
Sample Page
Author:
Mabwell
ESMO 2026 | Mabwell to Present Latest Clinical Data on Nectin-4-targeting ADC 9MW2821 for Triple Negative Breast Cancer in Oral Presentation
July 20, 2026
Mabwell Receives IND Clearance from NMPA for LILRB4/CD3-targeting TCE Bispecific Antibody 6MW5311
June 23, 2026
Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress
June 18, 2026
Mabwell’s 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease
June 4, 2026